Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor by Jilesen, A.P.J. (Anneke P. J.) et al.
ORIGINAL SCIENTIFIC REPORT
Postoperative Outcomes of Enucleation and Standard Resections
in Patients with a Pancreatic Neuroendocrine Tumor
Anneke P. J. Jilesen1 • Casper H. J. van Eijck2 • Olivier R. C. Busch1 •
Thomas M. van Gulik1 • Dirk J. Gouma1 • Els J. M. Nieveen van Dijkum1
Published online: 25 November 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Background Either enucleation or more extended resection is performed to treat patients with pancreatic neu-
roendocrine tumor (pNET). Aim was to analyze the postoperative complications for each operation separately.
Furthermore, independent risk factors for complications and incidence of pancreatic insufficiency were analyzed.
Methods Retrospective all resected patients from two academic hospitals in The Netherlands between 1992 and
2013 were included. Postoperative complications were scored by both ISGPS and Clavien–Dindo criteria. Based on
tumor location, operations were compared. Independent risk factors for overall complications were identified. During
long-term follow-up, pancreatic insufficiency and recurrent disease were analyzed.
Results Tumor enucleation was performed in 60/205 patients (29 %), pancreatoduodenectomy in 65/205 (31 %),
distal pancreatectomy in 72/205 (35 %) and central pancreatectomy in 8/205 (4 %) patients. Overall complications
after tumor enucleation of the pancreatic head and pancreatoduodenectomy were comparable, 24/35 (69 %) versus
52/65 (80 %). The same was found after tumor enucleation and resection of the pancreatic tail (36 vs.58 %). Number
of re-interventions and readmissions were comparable between all operations. After pancreatoduodenectomy, 33/65
patients had lymph node metastasis and in patients with tumor size B2 cm, 55 % had lymph node metastasis. Tumor
in the head and BMI C25 kg/m2 were independent risk factors for complications after enucleation. During follow-up,
incidence of exocrine and endocrine insufficiency was significant higher after pancreatoduodenectomy (resp. 55 and
19 %) compared to the tumor enucleation and distal pancreatectomy(resp. 5 and 7 % vs.8 and 13 %). After tumor
enucleation 19 % developed recurrent disease.
Conclusion Since the complication rate, need for re-interventions and readmissions were comparable for all
resections, tumor enucleation may be regarded as high risk. Appropriate operation should be based on tumor size,
location, and functional status of the pNET.
Introduction
Type of operation in patients with a pancreatic neuroen-
docrine tumor (pNET) primarily depends on tumor location
and tumor size [1, 2]. Besides a standard pancreatic
resection, such as pancreatoduodenectomy or distal pan-
createctomy, enucleation of a tumor in pancreatic head or
corpus/tail is frequently performed in patients with well-
defined, small pNET located away from the pancreatic
duct. Compared to pancreatic adenocarcinoma, pNETs
& Anneke P. J. Jilesen
a.p.jilesen@amc.uva.nl
1 Department of Surgery, Academic Medical Center,
Meibergdreef 9, PO Box 22660, 1105 AZ Amsterdam,
The Netherlands
2 Department of Surgery, Erasmus Medical Center, Rotterdam,
The Netherlands
123
World J Surg (2016) 40:715–728
DOI 10.1007/s00268-015-3341-9
have a much better prognosis after resection and therefore,
long-term postoperative outcome and pancreatic function
may be more relevant in these patients [2, 3].
Owing to the introduction of clear clinical grading
systems for pancreatic fistula, postoperative bleeding and
delayed gastric emptying by the International Study Group
of Pancreatic Surgery (ISGPS) [4–6], the severity of these
postoperative complications can now be categorized in
detail. Also using the Clavien–Dindo grading system, the
severity of the complications can be specified in terms of
need for re-intervention and organ failure [7].
In the most studies on postoperative outcome, patients
with different diagnoses are enrolled. This may affect the
outcome since the diagnosis ‘‘pancreatic neuroendocrine
tumor’’ is in itself a risk factor for developing pancreatic
complications, especially pancreatic fistula [8]. pNET are
often associated with a non-dilated pancreatic duct and
subsequently less inflammation and stromal changes in the
pancreatic parenchyma, which leads to a soft and friable
pancreas during surgery. These factors consequently
increase the pancreatic fistula rate after resection [8–14].
Furthermore, tumor enucleation is often compared with a
‘‘standard resection’’ while a standard resection carries no
uniform definition. Besides patients with a pancreatoduo-
denectomy or distal pancreatectomy, studies included
patients with total pancreatectomy or even central pan-
createctomy [15–17].
Aim of this study was to analyze postoperative com-
plications for different operations, in particular enucleation
versus standard resections, using both the ISGPS and
Clavien–Dindo grading system in patients with a pancre-
atic neuroendocrine tumor. Furthermore, we identified risk
factors for overall complications after resection. Finally,
the rate of pancreatic insufficiency was analyzed for the
operations assessed in this study.
Methods
Patients
All patients with resected pNET were included from the
Academic Medical Center (AMC) in Amsterdam and from
the Erasmus Medical Center (Erasmus MC) in Rotterdam,
both in The Netherlands, in the period January 1992
through December 2013. Both tertiary centers are high-
volume centers for pancreatic surgery and are also spe-
cialized in the treatment of neuroendocrine tumors.
Patients with extended combined operations were exclu-
ded. Eligible patients were identified from pathology
reports of all pancreatic resections. Patient and operation
characteristics, postoperative complications, and mortality
were extracted from the patient records. Based on the
operation, patients were stratified in different groups. A
hereditary syndrome is defined as multiple endocrine
neoplasia (MEN) syndrome or Von Hippel–Lindau
syndrome.
Pancreatic operations
Pancreatic enucleation
For small, superficial neuroendocrine tumors without a
connection or in close relation to the pancreatic duct a
pancreatic enucleation was performed while attempting not
to damage the pancreatic duct [18]. The decision was made
after imaging and during surgery based on tumor size,
superficial location, and the relation to the pancreatic duct.
In none of the patients with an enucleation, lym-
phadenectomy was carried out. Laparoscopic tumor enu-
cleation was introduced in the most recent years of the
study.
Pancreatic resection—pancreatoduodenectomy
For tumors located in the head of the pancreas, a pylorus-
preserving pancreatoduodenectomy (PPPD) or, if neces-
sary, a classical Whipple-Kausch pancreatoduodenectomy
was performed as described previously [19, 20]. Recon-
struction was carried out through an end-to-side pancre-
aticojejunostomy (PJ), end-to-side hepaticojejunostomy
(HJ), and a gastrojejunostomy (GJ) or duodenojejunostomy
(DJ) [21]. One silicon drain was left in the lesser sac [19].
Pancreatic resection—distal pancreatectomy
For tumors located in the body or the tail of the pancreas, a
distal pancreatectomy, with or without a splenectomy, was
the standard. Splenectomy was performed to ensure a
radical resection in case of a suspected malignant tumor or
an inadequate remaining blood supply to the spleen [22]. In
all patients, the pancreatic remnant was closed either with
sutures or a stapler. In the most recent years, laparoscopic
tail resection was introduced.
Pancreatic resection—central pancreatectomy
A central pancreatectomy was performed for tumors loca-
ted in the central part of the pancreas not suitable for
enucleation. Central pancreatectomy was performed when
the tumor was embedded deeply in the pancreatic tissue
with risk of damage to the pancreatic duct. Reconstruction
was performed using an end-to-side, duct-to-mucosa PJ to
secure internal drainage of the pancreatic tail remnant. The
proximal pancreatic stump was closed with sutures or a
surgical stapler. Central pancreatectomy enables the
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surgeon to perform a less extended, parenchyma preserving
resection compared to a complete corpus/tail resection [23,
24].
Peptide receptor radionuclide therapy (PRRT)
A specific group of patients (n = 12) from Erasmus MC,
with locally advanced pNET or hematogenous metastasis,
received preoperative treatment with PRRT before the
index operation [25]. After PRRT, patients had par-
tial/complete response of their primary tumor or metastases
and therefore were considered for resection.
Perioperative treatment with somatostatin analogs
Somatostatin analogs were routinely administered to
patients with a high risk of developing pancreatic fistula,
i.e., patients with a non-dilated pancreatic duct and/or soft
pancreatic tissue except in patients with insulinomas [13,
26]. Also patients with symptoms related to their NET may
have been treated with a somatostatin analog. The diameter
of the main pancreatic duct (MPD) was scored as\3 or
C3 mm based on radiological description on CT images or
on perioperative findings, using a cut-off value of C3 mm
for a dilated duct [27, 28].
Postoperative complications
The primary endpoint was the overall complication rate
after pancreatic surgery.
Complications were identified from the patient records.
Also the discharge letters and medical notes were checked
for reported complications. The medication list was
checked on the use of antibiotics and somatostatin analogs.
Laboratory tests and additional endoscopic or radiological
imaging or interventions during hospitalization were
reviewed to confirm whether they were performed to detect
or treat complications. The independent Dutch national
surgical complication registry used in both surgical
departments was consulted for possibly overlooked com-
plications [29]. All pathology specimens were reviewed
and if necessary rescored according the most recent WHO
classification of 2010 [30].
Severity of major complications after pancreatic surgery
was scored using both the ISGPS and the Clavien–Dindo
classification [7]. These major complications included:
pancreatic fistula grade B/C, delayed gastric emptying
grade B/C and postoperative bleeding grade B/C [4–6].
Grade A complications were not considered as major
complications since they had no clinical consequences. In
addition, other complications were recorded. Chylous
ascites was defined as a drain output with milky appearance,
occurring simultaneously with the start of enteral feeding
and confirmed with elevated triglyceride in the drain output
as reported previously [31]. Pneumonia, surgical site
infection, intra-abdominal abscess, and urinary tract infec-
tion were defined according to the Centers of Disease
Control and Prevention (CDC) guidelines [32–34]. In this
study, pneumonia was described as hospital-acquired
pneumonia. Readmission was understood to be a new
admission within 30 days after discharge from the initial
hospitalization. Re-intervention was understood to be a
surgical, endoscopic, or radiological re-intervention.
Tumors were divided into small (B2 cm) and large ([2 cm)
tumors, based on preoperative radiological imaging.
Resection margins are classified according the Royal Col-
lege of Pathologists [35] whereby tumors with microscopic
margin involvement\1 mm are classified as R1. Also in
patients with unclear margins due to the damage caused by
coagulation are classified as R1. Lymph node metastases in
the resected specimen were proven by pathology.
Long-term follow-up
Secondary endpoint was pancreatic insufficiency during
follow-up. Exocrine insufficiency was defined as the per-
sisting use of pancreatic enzymes as treatment for steat-
orrhea at least 6 months after surgery. Endocrine
insufficiency was defined as the development of diabetes
mellitus after surgery. Patients with preexisting diabetes
mellitus or preexisting exocrine insufficiency were exclu-
ded from the analysis.
Data analyses
Statistical analysis was performed using IBM SPSS
statistics version 20.0 (IBM Corp. Armonk, NY: IBM
Corp.). Based on the type of outcome data, the unpaired
t test, Mann–Whitney U test or the v2 d test, was used. The
continuous variables are described with the interquartile
range (IQR) or range. Postoperative outcome was com-
pared in two different groups; patients with a tumor enu-
cleation of the pancreatic head were compared with
patients with pancreatoduodenectomy, and patients with a
tumor enucleation of pancreatic corpus/tail were compared
with a distal pancreatectomy. A univariable analysis was
performed to identify risk factors for overall complications.
The factors with a p value \0.1 were analyzed in the
multivariable logistic regression analysis to identify inde-
pendent risk factors. A p value below 0.05 was considered
significant. Missing values were imputed using multiple
imputations [36]. The group of patients with a central
pancreatectomy (n = 8) was too small to perform statisti-
cal testing, therefore only the exact numbers are displayed
in tables. Long-term follow-up was presented as median in
months.
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Results
Overall 10 patients were excluded since they underwent
extended combined operations. One patient underwent a
liver transplantation and distal pancreatectomy simultane-
ously, two patients underwent hemihepatectomy and distal
pancreatectomy simultaneously and four patients received
both wedge resection of liver metastasis and radiofre-
quency ablation (RFA) of liver metastasis in combination
with a distal pancreatectomy. The other three patients were
excluded because resection was atypical; total pancreate-
ctomy in two patients and duodenum preserving pancreatic
head resection in one patient. Finally, a total of 205
patients with pNET with mean age of 52.5 years were
included, 93 patients (45 %) were male and 112 were
female (55 %). Sixty were treated with tumor enucleation,
65 with pancreatoduodenectomy, 72 with distal pancrea-
tectomy, and 8 with a central pancreatectomy. Character-
istics of the different groups of patients are listed in
Table 1.
Perioperative outcomes
The mean operation time for tumor enucleation was
200 min, significantly shorter than that for pancreatoduo-
denectomy or distal pancreatectomy, i.e., 403 and 260 min.
In total, 35/60 (58 %) pNET treated with tumor enucleation
were located in the pancreatic head of which 2/35 were
operated laparoscopically with one conversion. The other
25 patients had a tumor enucleation of the pancreatic
corpus/tail, nine patients were operated laparoscopically
with four conversions to an open procedure. Seventeen of
the 72 distal pancreatectomies were laparoscopic opera-
tions, and 8 of these (47 %) were converted to an open
operation.
Postoperative outcomes
Overall, 132/205 patients (64 %) had one or more com-
plications. The complication rates after tumor enucleation
of the head versus pancreatoduodenectomy were not sig-
nificant different with 69 and 80 %, respectively
(p = 0.20) (Table 2). The overall complication rates after
tumor enucleation of corpus/tail versus distal pancreatec-
tomy were 36 and 58 %, respectively (p = 0.054).
Median in-hospital stay was 12 days (IQR 9–17). The
median in-hospital stay was significantly prolonged in
patients with complications (14 days IQR 10–25) compared
to patients without complications (10 days, IQR 7–13),
p\ 0.001. In patients with complications, the in-hospital
staywas not significantly different after tumor enucleation of
pancreatic head, i.e., 17 days (range 5–136) compared to
16 days after pancreatoduodenectomy (range 7–88 days)
p = 0.73. As depicted in Fig. 1, the interquartile range of the
in-hospital stay after tumor enucleation of the pancreatic
head and pancreatoduodenectomy was broad: i.e.,
10–33 days and 12–30 days. Most patients with complica-
tions were discharged from the hospital within 21 days, but a
considerable number of patients had a prolonged length of
hospital stay. Nine of the 35 (26 %) patients after tumor
enucleation of the pancreatic head, and 18/65 (28 %)
patients after pancreatoduodenectomy were admitted to the
Fig. 1 In-hospital stay in patients with complications for each operation separately. • outlier patients
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hospital C21 days (p = 0.8). In addition, there were some
extreme outliers consisting patients with an in-hospital
stay of[ 80 days due to complications. In-hospital stay
in 9/25 (36 %) patients with complications after tumor
enucleation of the pancreatic corpus/tail and 42/72 (58 %)
patients after distal pancreatectomy were comparable, i.e.,
10 days (range 5–147) versus 11 days (range 3–74)
p = 0.41.
Significantly more patients suffered from clinically rel-
evant pancreatic fistula (grade B/C) after tumor enucleation
of pancreatic head (40 %) compared to pancreatoduo-
denectomy (14 %), p\ 0.01. The severity of the major
complications based on the Clavien-Dindo classification
was not significantly different between the different oper-
ations (see Table 2). Overall, 62/205 patients (30 %) had a
grade B/C complication according to the ISGPS criteria,
e.g., pancreatic fistula, postoperative bleeding or delayed
gastric emptying. Based on the Clavien-Dindo grading
system severity cut-off value of C3, 15 % of the patients
(9/62) with a grade B/C complication were missed. In these
9 patients with a grade B/C pancreatic fistula, the periop-
erative drain was used for drainage of abscesses, and
therefore there was no need for a re-intervention. These
nine patients had a Clavien–Dindo severity score grade II.
Although the number of operated patients increased over
time, the incidence of major complications remained the
same.
The number of readmissions within 30 days after dis-
charge was 14 % (n = 5) after tumor enucleation of pan-
creatic head compared to 23 % (n = 15) after
pancreatoduodenectomy (p = 0.30). The number of read-
missions after tumor enucleation of corpus/tail was 8 %
(n = 2) compared to 10 % (n = 10) in patients after distal
pancreatectomy (p = 0.80).
Fig. 2 Distribution between
pathology, operation, and tumor
type after surgical resection in
patients with pancreatic
neuroendocrine tumor
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Rates of re-interventions and readmissions did not differ
between tumor enucleation of the pancreatic head (49 %)
and pancreatoduodenectomy (46 %) p = 0.82 or between
enucleation of pancreatic corpus/tail tumors (24 %) and
distal pancreatectomy (19 %) p = 0.63. Also after further
subdivision in endoscopic, radiological, and surgical re-
interventions, no significant differences were found
between the operations.
The incidence of other, miscellaneous complications
was higher after pancreatoduodenectomy (34 %) compared
to tumor enucleation of pancreatic head (17 %) p = 0.08
and significantly higher after distal pancreatectomy (14 %)
compared to tumor enucleation of pancreatic corpus/tail
(0 %) p\ 0.05. The most frequent other complications
were chylous ascites in 9 patients, pneumonia in 6 patients,
and urinary tract infection in 6 patients.
In-hospital mortality was 1.5 % (3/205); all deaths were
related to pancreatoduodenectomy. One patient died after
an unexpected and unsuccessful attempt at cardiopul-
monary resuscitation after a cardiac arrest. The patient had
no signs of abdominal sepsis or multiple organ failure. The
second patient died due to respiratory insufficiency after an
aspiration pneumonia associated with abdominal sepsis and
pancreatic fistula. The third patient died due to cardiac
complications after extensive perioperative blood loss in
combination with a medical history of tricuspid insuffi-
ciency and mitral valve replacement.
Risk factors for overall complications
A univariable analysis was performed to identify risk fac-
tors for overall complications of the three different types of
resections, see Table 3. Regarding enucleation, a tumor
located in the pancreatic head and BMI[25 kg/m2 were
significant risk factors in the univariable analysis and in the
multivariable analysis both factors were independent risk
factors with an odds ratio of, respectively, 4.4 (95 %CI
1.4–11.2) and 3.5 (95 %CI 1.1–11.0). Regarding pancre-
atoduodenectomy, no risk factors were found in the uni-
variable analysis, and therefore no multivariable analysis
was performed. Regarding distal pancreatectomy, BMI
[25 kg/m2 and diabetes mellitus were risk factors in the
univariable analysis but in the multivariable analysis no
independent risk factors were found.
Oncological outcome
Lymphadenectomy was not a standard part of the operation
in patients with tumor enucleation. In patients with a
lymphadenectomy, 46 patients had a tumor size B2 cm and
99 patients had a tumor size[2 cm. Patients with a larger
tumor size had significantly more often lymph node
metastasis: 38/99 patients with a tumor size [2 cm had
lymph nodes metastasis (38 %) compared to 7/46 patients
with a tumor size B2 cm (15 %), p = 0.005. This also
applies for the 11/72 patients after distal pancreatectomy
with lymph node metastasis. Patients with a tumor size
[2 cm (n = 10/41) had significantly more often lymph
node metastasis compared to patients with a tumor size
B2 cm (n = 1/31), p = 0.013. After pancreatoduodenec-
tomy, 33/65 patients had lymph node metastasis. 50 % of
the patients with a tumor size [2 cm (n = 27/54) had
lymph node metastasis compared to 55 % of the patients
with a tumor size B2 cm (n = 6/11), p = 0.78. Excluding
patients after tumor enucleation, patients with a tumor
located in the pancreatic head had significantly more often
lymph node metastasis (n = 33/65) compared to patients
with a pNET in corpus/tail (n = 13/80), p\ 0.001.
Distribution of tumor grade, operations, and tumor
functionality is displayed in Fig. 2. Compared with patients
after pancreatoduodenectomy, significantly more patients
had a tumor grade 1 in tumors enucleated from the pan-
creatic head, i.e., 51 versus 94 %, p\ 0.01. Two patients
(6 %) after tumor enucleation of the pancreatic head had a
tumor grade 2. One patient had a tumor size of 10 mm and
the other had a tumor size of 15 mm. After tumor enu-
cleation in pancreatic corpus/tail, 23/25 of the patients had
tumor grade 1 (92 %) compared to 51/72 patients after
distal pancreatectomy (71 %), p\ 0.05. Two patients
(8 %) had a grade 2 pNET after tumor enucleation of
pancreatic corpus/tail, both nonfunctional pNET (NF-
pNET).
As depicted in Table 1, a tumor enucleation was often
performed in patients with a functional pNET. Of the 26
patients with a functional pNET in the pancreatic head,
20 patients had an insulinoma (77 %) and six patients
had a gastrinoma (23 %). Of the 18 functional pNET in
the pancreatic corpus/tail, 17 (94 %) had an insulinoma
and 1 patient had a gastrinoma. Only five patients had a
functional pNET after pancreatoduodenectomy: 3 patients
had a gastrinomas, 1 patients a VIPoma, and 1 patient a
glucagonoma. In patients after distal pancreatectomy,
26/72 patients had a functional pNET. Of these 26
patients, 21 patients had an insulinoma, 3 patients a
gastrinoma, 1 patient a VIPoma and 1 patient a gluca-
gonoma. Of all insulinomas patients, only one patient had
one positive lymph node in the resected specimen. This
patient had a distal pancreatectomy with a tumor diam-
eter of 2.5 cm.
Of the patients with a tumor size B2 cm, 86/95 (91 %)
had a grade 1 tumor compared to 60/110 (55 %) patients
with a tumor size[2 cm, p\ 0.01. None of the pNETs
with a tumor size\2 cm had a grade 3 tumor. All 10 grade
3 tumors were NF-pNET and the median tumor size was
43 mm (IQR 35–76). In patients with a tumor B1 cm
(n = 14), all patients had a grade 1 tumor and 2 patients
World J Surg (2016) 40:715–728 723
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had lymph nodes metastasis (14 %). These two patients
were diagnosed with gastrinoma.
R1 resection margins were more often found after tumor
enucleation of pancreatic head (37 %) compared to pan-
creatoduodenectomy (17 %) p = 0.052. After tumor enu-
cleation of corpus/tail and distal pancreatectomy, the
differences were more comparable, i.e., 24 % versus 17 %,
p = 0.50.
Long-term follow-up
Functional follow-up was available for all included
patients, with a median follow-up time of 29 months (IQR
10–64). Significantly more patients developed endocrine
(19 %) and exocrine insufficiency (55 %) after pancreato-
duodenectomy compared to tumor enucleation (7 and 5 %)
or distal pancreatectomy (13 and 8 %) (p\ 0.001), see
Table 4. There were no significant differences between
tumor enucleation and distal pancreatectomy regarding the
rate of pancreatic insufficiency.
Long-term oncologic follow-up was only available in
patients with NF-pNET. However, 3/58 patients with an
insulinomas developed tumor recurrence, all after distal
pancreatectomy. Of the 130 patients with NF-pNET, 14
patients were excluded from long-term follow-up since 11
patients already had metastasis preoperatively and 3
patients died due to postoperative complications. There-
fore, 116 patients with NF-pNET were available for long-
term analysis. Median follow-up for recurrent disease was
37 months (IQR 18-60 months). Of the 116 patients, 16
patients have had a tumor enucleation, 50 patients a pan-
creatoduodenectomy, 42 patients a distal pancreatectomy,
and 8 patients a central pancreatectomy. During oncolog-
ical follow-up, 37 patients developed recurrent disease of
which 15 patients died due to tumor progression. Of the 37
patients with recurrent disease, 68 % was proven by
pathology (n = 25/37), the other 12 patients were proven
by long-term follow-up. After enucleation, 19 % of
patients developed recurrent disease (n = 3/16) of which 1
patient died. Tumor recurrence was significantly more
frequent after pancreatoduodenectomy (n = 23) compared
to tumor enucleation (n = 3) or distal pancreatectomy
(n = 10). There were no significant differences in tumor
recurrence or tumor related death between tumor enucle-
ation and distal pancreatectomy.
Discussion
This is the first study in patients with pancreatic neuroen-
docrine tumors which describes the postoperative outcomes
of different operations separately using both ISPGS criteria
and the Clavien–Dindo grading system. Besides the higher
rate of grade B/C pancreatic fistula after tumor enucleation
of pancreatic head, the postoperative outcomes were
comparable between all operations. A tumor in the pan-
creatic head and a high BMI were independent risk factors
for complications in patients after tumor enucleation.
During follow-up, the rate of pancreatic insufficiency was
significantly higher after pancreatoduodenectomy but there
were no differences in the rate of pancreatic insufficiency
after tumor enucleation or distal pancreatectomy.
The main complications after pancreatic surgery in
patients with a pNET were pancreatic fistula grade B/C.
The rate of these fistulas was the highest after tumor enu-
cleation (31 %), especially after tumor enucleation in the
pancreatic head (40 %). Other studies also report a high
rate of pancreatic fistula after tumor enucleation [8, 37, 38].
Table 4 Long-term outcome in patients with pancreatic neuroendocrine tumor after surgical resection
Tumor
enucleation
(TE)
Pancreatoduodenectomy
(PD)
Distal
pancreatectomy
(DP)
TE versus
PD
(p value)
TE versus
DP
(p value)
PD versus
DP
(p value)
Central
pancreatectomy
All resected patients N = 60 N = 65 N = 72 N = 8
Functional follow-up
Exocrine
insufficiency
3 (5)a 34 (55)c 6 (8) \0.001 0.5 \0.001 0
Endocrine
insufficiency
4 (7)b 11 (19)d 8 (13)e 0.05 0.3 0.3 2 (25)
a 1 patient was excluded since preexisting exocrine insufficiency n = 59 patients were available for analysis
b 1 patients was excluded since preexisting diabetes mellitus n = 59 patients were available for analysis; one of the 4 patients with endocrine
insufficiency have had multiple pancreatic resections
c 3 patients were excluded since postoperative mortality n = 62 patients were available for analysis
d 7 patients were excluded since preexisting diabetes mellitus/postoperative mortality n = 58 patients were available for analysis
e 8 patients were excluded since preexisting diabetes mellitus n = 64 patients were available for analysis; one of the 8 patients with endocrine
insufficiency have had multiple pancreatic resections
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In addition, due to the severe complications (pancreatic
fistula, postoperative bleeding and delayed gastric empty-
ing) the in-hospital stay, the need for re-interventions and
readmissions were also comparable between tumor enu-
cleation, pancreatoduodenectomy, and distal pancreatec-
tomy. This is remarkable since tumor enucleation is often
described as a minimally invasive operation with only an
increased risk for pancreatic fistula. During follow-up, no
differences were seen in the rate of pancreatic insufficiency
between tumor enucleation and distal pancreatectomy. A
high rate of pancreatic insufficiency was seen after pan-
creatoduodenectomy. Altogether, tumor enucleation can be
regarded a high risk operation with considerable risk for
postoperative morbidity. In fact, laparoscopic tail resection
may be an attractive option compared to tumor enucleation
[39, 40]. The learning curve of laparoscopic tail resection
may be achieved faster than laparoscopic tumor enucle-
ation. Laparoscopic tumor enucleation will probably be
carried out less frequently since laparoscopic tumor enu-
cleation is usually not indicated for malignant diseases.
Further studies are needed to support this hypothesis.
The Clavien–Dindo grading system and the ISGPS cri-
teria are both often used as scoring methods to describe the
severity of postoperative complications [4–7]. In the Cla-
vien–Dindo grading system, a cut-off value C 3 is often
used to describe severe complications [21, 27, 41, 42].
According to the ISGPS criteria, grade B/C complications
are also severe complications. In our study, 15 % of the
severe grade B/C complications were missed if only the
Clavien–Dindo grading system with a cut-off B3 was used,
especially in the analysis of pancreatic fistula. In some
patients with a grade B/C pancreatic fistula, no additional
re-intervention was needed, since the perioperative drain
was used for abscess drainage. Future studies should be
aware of this difference.
Overall morbidity rate was 64 % and mortality rate after
pancreatoduodenectomy was 4.6 %. These rates seems
slightly higher compared to the contemporary literature
[43–46]. This can be explained by the extended inclusion
period from 1992 to 2013. The number of operated patients
increased during this inclusion period; with the central-
ization of pancreatic surgery, morbidity rates will also be
reduced [47]. The rate of exocrine insufficiency was rela-
tively high with 55 % since other studies report a incidence
between 17 and 43 % [18, 48, 49]. This can be explained
by the use of different definitions of exocrine insufficiency
and the prolonged survival in patients with pNET.
The pancreatic fistula rate of 18 % after pancreatoduo-
denectomy in this study is slightly higher than the 2–15 %
rates reported in literature [5, 8, 50, 51]. This could easily
be explained by the reassessment of the complications by
an independent researcher according the ISGPS criteria and
Clavien–Dindo grading system. Furthermore, the increased
rate of pancreatic fistula may be explained by the texture of
the pancreatic remnant. Most of our patients undergoing
PD and distal pancreatectomy for small pNET had a soft
gland with small MPD. The studies with a lower rate of
pancreatic fistula have included patients with different
types of pancreatic neoplasm or even chronic pancreatitis
while a neuroendocrine tumor itself is a risk factor for
pancreatic fistula [8, 37]. In addition, enucleation of pNET
located 2–3 mm distant from the main pancreatic duct is a
risk factor for pancreatic fistula [52, 53]. During tumor
enucleation, we attempt to preserve the pancreatic duct.
Nevertheless, pancreatic fistula is the major cause for
postoperative morbidity in patients with pNETs. In our
study, tumor enucleation was not performed in deeply
located pNET because these tend to have a close rela-
tionship with the main pancreatic duct (MPD). Also, size of
the MPD was not predictive for the occurrence of PF, most
likely due to the fact that in only 3/60 enucleated patients,
the MPD was dilated (Tables 1 and 3). Data regarding the
exact relationship between tumor and MPD was not
available and an intraoperative ultrasound to measure the
distance between MPD, and the tumor was not routinely
performed in all patients. However, we do realize that the
distance between the tumor and MPD could affect the PF
rate. It is a challenge to reduce the rate of pancreatic fistula
after pancreatic enucleation. Different techniques with
varying success rates are discussed in the literature, such as
a teres hepatis ligament flap plasty to cover the enucleation
site, placement of an internal pancreatic duct stent or
prophylactic use of somatostatin analogs [54–58]. Despite
all these efforts, pancreatic fistula remains a problem after
pancreatic resections and particularly in patients with
pNET.
The present study is one of the largest studies in patients
with pNET in which postoperative outcomes were com-
pared between pancreatic enucleation and standard pan-
creatic resection. However, a limitation of this study is its
retrospective design. The choice of the type of resection is
made by the surgeon after multidisciplinary consultation
and may be influenced by tumor size or other factors.
Furthermore, the study period was relatively long encom-
passing a period of 21 years. Potential underreporting of
pancreatic fistula/DGE/postoperative bleeding grade A
may have occurred in the early years of the study period.
The course of these complications is mild and therefore
they are not always explicitly recorded in the discharge
letters or patient records. The accuracy of scoring of
postoperative complications, especially pancreatic fistula,
has increased in recent years with the implementation of
the ISGPS criteria. In order to reconcile, all the compli-
cations with the current standards, not only the discharge
letter but also the entire patient record including laboratory
results, medication list, and radiology results was screened
World J Surg (2016) 40:715–728 725
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for postoperative complications. Furthermore, the rate of
pancreatic insufficiency should be carefully interpreted.
Because of the retrospective character of the study, it was
not always possible to determine whether the patients had
developed endocrine insufficiency because of their surgery
or due to other causes. Also the number of patients with
exocrine insufficiency may have been slightly underesti-
mated since the use of pancreatic enzymes will not always
be documented accurately and no objective tests like
elastase-1 in the stool was performed.
Since this study was not randomized, the choice for a
tumor enucleation or resection was made by the surgeon.
Therefore, selection bias may have occurred in the choice
of the pancreatic operation. As depicted in Table 1, some
patients and tumor characteristics were not comparable
between the groups, such as the diameter of the pancreatic
duct. An enucleation is often performed in patients with a
small pancreatic duct (Table 1) which can increase the
incidence of pancreatic fistula, especially in the head of the
pancreas. The conversion rate of laparoscopic resection
was relatively high because of the learning curve of the
surgeons [59]. In the patients with a converted distal pan-
createctomy, the tumor was small or challenging to local-
ize. Another limitation of this study is that we did not
perform a standard lymph node resection in patients
undergoing enucleation. Even in tumors smaller than 2 cm
located in the pancreatic head, we found lymph node
metastasis in 6 of the 11 patients (55 %). Since no infor-
mation was available about the presence of lymph node
metastasis in patients after tumor enucleation located in the
pancreatic head, it was not possible to determine the exact
number of metastasis in these small tumors. In this study,
R1 resection margin was defined as tumors with micro-
scopic margin involvement\1 mm, not only at the pan-
creatic resection margin but also at the anterior and
posterior margin as well as the median margin close to the
portal vein and mesenteric artery. Patients with unclear
margins caused by coagulation damage were also scored as
R1. Since these strict criteria, the incidence of patients with
a positive margin after distal pancreatectomy and pancre-
atoduodenectomy was relatively high (17 %) compared to
studies with other criteria [60].
In conclusion, a comparison was made between enu-
cleation versus pancreatoduodenectomy or distal pancrea-
tectomy to illustrate the differences in outcomes.
Postoperative morbidity after enucleation of pancreatic
neuroendocrine tumors was comparable to a pancreato-
duodenectomy or distal pancreatectomy and therefore it is
not to be considered an easy, low-risk operation. In addi-
tion, the presence of lymph node metastasis was high for
small tumors located in the pancreatic head and 19 % of
the NF-pNET patients developed recurrent disease after
tumor enucleation. Therefore, a pancreatoduodenectomy
might be the preferred operation for most pNET that reside
in the head of the gland except for superficially located
insulinomas that typically have low malignant potential. In
addition, a formal resection of corpus/tail tumors may also
be more desirable than enucleation of certain tumors. The
data from this study may guide surgeons in selecting
appropriate operations for pancreatic neuroendocrine
tumors, based upon size, location, and functional status.
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